Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06308861
Other study ID # JH-201-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date August 12, 2020
Est. completion date July 13, 2021

Study information

Verified date March 2024
Source J2H Biotech
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

1. Research Purpose: To evaluate the safety, tolerability, pharmacokinetic/pharmacodynamic properties of J2H-1702 (a candidate for treatment of non-alcoholic steatohepatitis) in healthy men. 2. Design: A dose block-randomized, double-blind, placebo controlled, single- and multiple dosing, dose-escalation phase 1 clinical trial


Description:

Subjects in all dose groups will be randomized to the study group (J2H-1702 group) and the control group (Placebo group) in a 8:2 ratio. Adverse event (AE) collection, physical examination, vital signs, ECG, clinical laboratory tests, etc. will be performed to assess the safety and tolerability, and blood and urine sampling will be performed to assess the PK/PD characteristics. In addition, blood sampling for mass cytometry (multiple administration study) and baseline fibroscan will be performed for the exploratory evaluation.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date July 13, 2021
Est. primary completion date June 25, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 45 Years
Eligibility Inclusion Criteria: 1. A healthy male adult within the range of 19 to 45 years old 2. BMI=18.0~27.0kg/m2 (Body mass index, BMI) 3. A subject confirmed to be clinically healthy based on the medical history, physical examination, vitals signs, ECG, and appropriate clinical laboratory tests 4. A subject who his spouse or partner agrees to use dual contraceptive methods and not to donate sperms 5. A subject who has voluntarily agree to participate in the study Exclusion Criteria: 1. A subject who had or has the disease corresponding to clinically significant liver, etc. 2. A subject with a history of gastrointestinal diseases or surgery 3. A subject who has a history of clinically significant hypersensitivity to drugs containing 11ß-HSD1 inhibitor 4. A subject who has genetic problems such as galactose intolerance, Lap galactose intolerance, Lap lactase deficiencies, or glucose ·galactose malabsorptivity, etc. 5. One who has drug abuse and one who is positive response in urine drug screening tests 6. A subject with abnormal vital signs at the screening visit 7. A subject who has participated in another clinical trial or bioequivalence test 8. A subject who donated whole blood or the ingredient, or received blood transfusion 9. A subject who took drug metabolizing enzyme-inducing and inhibitory drugs 10. A subject who consumes grapefruit/caffeine-containing food 11. A subject who took any prescription drug or herbal medicine or took any Over The Counter Drug (OTC) 12. High caffeine intaker, high alcohol intaker or excessive smoker 13. A subject who cannot eat meals provided by the Clinical Trial institution. 14. A subject who participated in this trial and were administered the investigational product. 15. A subject who is positive for serum test 16. A subject who the investigator deems inappropriate for this clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Single administration Amg dose Group
Orally, Amg tablet single administration
Single administration Bmg dose Group
Orally, Bmg tablet single administration
Single administration Cmg dose Group
Orally, Cmg tablet single administration
Single administration Dmg dose Group
Orally, Dmg tablet single administration
Single administration Emg dose Group
Orally, Emg tablet single administration
Single administration Amg dose Group-Placebo
Orally, Placebo Amg tablet, single administration
Single administration Bmg dose Group-Placebo
Orally, Placebo Bmg tablet, single administration
Single administration Cmg dose Group-Placebo
Orally, Placebo Cmg tablet, single administration
Single administration Dmg dose Group-Placebo
Orally, Placebo Dmg tablet, single administration
Single administration Emg dose Group-Placebo
Orally, Placebo Emg tablet, single administration
Multiple administration Amg dose group
Orally, Amg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Bmg dose group
Orally, Bmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Cmg dose group
Orally, Cmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Dmg dose group
Orally, Dmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Emg dose group
Orally, Emg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Amg dose group - Placebo
Orally, Placebo Amg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Bmg dose group - Placebo
Orally, Placebo Bmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Cmg dose group - Placebo
Orally, Placebo Cmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Dmg dose group - Placebo
Orally, Placebo Dmg 1 tablet, once a day for 3 days, multiple administration
Multiple administration Emg dose group - Placebo
Orally, Placebo Emg 1 tablet, once a day for 3 days, multiple administration

Locations

Country Name City State
Korea, Republic of J2H Biotech Suwon Gyeonggi-do

Sponsors (1)

Lead Sponsor Collaborator
J2H Biotech

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax Pharmacokinetics 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours (After IP administration)
Primary Emax Pharmacodynamics -1day 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12 hours, 1day 0 (Before IP administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24hours (After IP administration)
See also
  Status Clinical Trial Phase
Recruiting NCT05945537 - A Study of INI-822 in Healthy Volunteers and Participants With Non-alcoholic Steatohepatitis (NASH) or Presumed NASH Phase 1
Recruiting NCT05462353 - Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASH Phase 2
Recruiting NCT05065593 - The Effect of Aerobic and Resistant Exercise Training in Patients With Non-Alcoholic Steatohepatitis N/A
Terminated NCT04171765 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT04365855 - The Olmsted NAFLD Epidemiology Study (TONES) N/A
Active, not recruiting NCT02912260 - Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT06054815 - Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH Phase 2
Completed NCT02784444 - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH Phase 2
Not yet recruiting NCT06160271 - Study of Liver Fibrosis Stage Assessment by Fibroblast Activation Protein Imaging in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis Phase 2
Active, not recruiting NCT05573204 - Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients With Non-alcoholic Steatohepatitis Phase 2
Completed NCT04042142 - Glucagon Resistance in Patients With NAFLD N/A
Completed NCT04657523 - Ultrasound-Based Liver Fat Quantification (LFQ) Pilot Study N/A
Completed NCT04142424 - A Study to Understand the Safety, Tolerability, and Activity of Drug in Body Over a Period of Time of AZD2693, in Subjects of Non-Childbearing Potential in Overweight But Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects Phase 1
Terminated NCT02787304 - Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Phase 2
Recruiting NCT04666402 - Integrated Diagnostics for Early Diagnosis of Liver Disease
Completed NCT02528305 - The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis N/A
Recruiting NCT01056133 - Effect of Fish-oil on Non-alcoholic Steatohepatitis (NASH) Phase 2
Completed NCT02960204 - Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Phase 2
Completed NCT04806750 - Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension Phase 2
Recruiting NCT05751720 - Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue Phase 1/Phase 2